AbbVie
ABBV
$250.94
-2.51%
AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Humira, and Botox. As a top-tier player in the pharmaceutical industry, AbbVie has successfully navigated the Humira patent cliff through the rapid growth of its next-generation immunology portfolio and strategic acquisitions like Allergan, Cerevel, and ImmunoGen. The current investor narrative centers on the company's post-Humira recovery, driven by Skyrizi and Rinvoq, a deep pipeline including weight-loss and eczema drugs, and the recent $10.9 billion Apogee Therapeutics acquisition to extend its immunology dominance. Additionally, the stock's strong performance and dividend growth have attracted attention, though concerns about valuation and FDA setbacks for certain drugs remain.…
ABBV
AbbVie
$250.94
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating: Buy. AbbVie is a compelling buy due to its successful post-Humira transition, strong growth from Skyrizi and Rinvoq, and attractive forward valuation. The consensus rating is 'Buy' with an average target of $268.68, implying 7.1% upside. The forward PE of 15.4x is below the sector average of 18-20x, and revenue growth of 12.4% YoY is accelerating. Gross margin improved to 71.9%, and free cash flow is robust at $20.9B TTM. The main risks are high debt, regulatory setbacks, and potential overvaluation after a strong rally. This Buy would be downgraded to Hold if forward PE exceeds 20x or revenue growth falls below 8%. Overall, the stock is fairly valued relative to its growth prospects.
Sign up to view all
ABBV 12-Month Price Forecast
The AI assessment is bullish with medium confidence. AbbVie's strong growth, attractive forward valuation, and defensive characteristics support a positive outlook. However, the high debt and regulatory risks temper confidence. The stance would be upgraded to high confidence if revenue growth exceeds 15% and forward PE remains below 16x, or downgraded to neutral if pipeline setbacks occur or debt levels worsen.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $270.39 and implied upside of +7.8% versus the current price.
Average Target
$270.39
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
AbbVie is covered by 28 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.74 (where 1 is Strong Buy and 5 is Sell). The average price target is $268.68, implying an upside of approximately 7.1% from the current price of $250.94. The distribution of ratings is bullish, with recent actions from major firms like UBS (Neutral), BMO Capital (Outperform), Wells Fargo (Overweight), and JP Morgan (Overweight) indicating a positive sentiment. The high target of $328 suggests that some analysts see significant upside, likely driven by pipeline success and continued growth in immunology, while the low target of $200 reflects concerns about competition and regulatory risks. The relatively narrow spread between the low and high targets (64%) indicates moderate uncertainty, but the overall consensus is optimistic, supported by the company's strong fundamentals and strategic acquisitions.
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a balanced bull-bear case. The bull case is supported by strong revenue growth from Skyrizi and Rinvoq, a forward PE below peers, and a robust pipeline. The bear case highlights financial leverage, regulatory setbacks, and potential overvaluation after a strong rally. Currently, the bull case has stronger evidence due to the company's successful post-Humira transition and attractive forward valuation. The key tension is whether the market's expectation of earnings growth (implied by the wide PE gap) will be met, as any shortfall could lead to multiple compression.
Bullish
- Skyrizi and Rinvoq driving growth: Q1 2026 revenue grew 12.4% YoY to $15.0B, driven by Skyrizi ($4.5B) and Rinvoq ($2.1B), which are offsetting Humira's decline ($0.7B). This shows successful post-Humira transition.
- Forward PE at discount to peers: Forward PE of 15.4x is below the sector average of 18-20x, indicating the market is not fully pricing in the growth potential. This suggests undervaluation relative to peers.
- Strong dividend and Dividend King status: AbbVie is a Dividend King with a yield of 2.87% and a payout ratio of 275.8%, reflecting a commitment to returning capital. The $10.9B Apogee acquisition is expected to support long-term dividend growth.
- Robust pipeline and strategic acquisitions: The Apogee acquisition and pipeline drugs for weight-loss and eczema provide long-term growth optionality. Recent acquisitions (Cerevel, ImmunoGen) diversify revenue beyond immunology.
Bearish
- Elevated trailing PE due to charges: Trailing PE of 96.4x is distorted by one-time charges and impairments, but it signals that current earnings are depressed. The gap between trailing and forward PE implies significant earnings growth is expected, which may not materialize.
- High debt levels and negative equity: Debt-to-equity ratio is -21.1x, indicating negative shareholders' equity, a red flag for financial stability. Interest expenses of $717M in Q1 2026 weigh on net income.
- FDA rejection for TrenibotE: The FDA rejection on manufacturing issues for TrenibotE is a near-term setback, though not a failure of the drug's science. It highlights regulatory risks that could delay pipeline monetization.
- Potential overvaluation after recent rally: The stock is up 32.8% over the past year and recently hit a 52-week high. With a PS ratio of 6.65x, the market may have already priced in much of the good news, limiting upside.
ABBV Technical Analysis
AbbVie's stock is in a strong uptrend, with a 1-year price change of +32.76%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $250.94 sits near the upper end of its 52-week range, at approximately 94% of the range (from a low of $189.79 to a high of $267.47). This positioning near the highs suggests robust momentum, though it also raises the risk of overextension. The stock's beta of 0.283 indicates it is significantly less volatile than the broader market, making it a defensive holding, but its recent surge has been notable.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$267
Price range past year
Annual Return
+32.8%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | -0.0% | +0.3% |
| 3m | +21.5% | +4.0% |
| 6m | +12.5% | +8.3% |
| 1y | +32.8% | +20.2% |
| ytd | +9.4% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue trajectory is accelerating, with Q1 2026 revenue of $15.0 billion, up 12.4% year-over-year, compared to Q1 2025 revenue of $13.3 billion. The growth is driven by Skyrizi ($4.5 billion) and Rinvoq ($2.1 billion), which are offsetting Humira's decline ($0.7 billion). The company's gross margin remains strong at 71.9% in Q1 2026, up from 70.0% in the year-ago quarter, reflecting a favorable product mix. Net income for Q1 2026 was $699 million, a significant improvement from the $1.3 billion in Q1 2025, but the net margin of 4.7% is lower than the 9.6% in Q1 2025 due to higher operating expenses and interest costs. The company's profitability is stable, with an operating margin of 31.6% in Q1 2026, though it faces headwinds from increased R&D spending ($2.5 billion) and interest expenses ($717 million).
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given AbbVie's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 96.4x, while the forward PE is 15.4x, indicating the market expects significant earnings growth. This wide gap suggests that the market is pricing in a substantial recovery in earnings, likely driven by the ramp-up of Skyrizi and Rinvoq and cost synergies from recent acquisitions. Compared to the industry average, AbbVie's forward PE of 15.4x is at a discount to the sector, which typically trades at 18-20x, making it attractive relative to peers. However, the trailing PE is elevated due to one-time charges and impairments, so the forward multiple is more indicative of the company's valuation. Historically, AbbVie's PE has ranged from 15x to 84x over the past few years, with the current forward PE near the lower end, suggesting the stock is reasonably valued relative to its own history.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, AbbVie carries a high debt burden with a negative debt-to-equity ratio of -21.1x, reflecting negative equity due to impairments and buybacks. Interest expenses of $717M in Q1 2026 reduce net income, which fell to $699M from $1.3B a year ago. The net margin of 4.7% is down from 9.6%, indicating pressure on profitability. However, free cash flow remains strong at $20.9B TTM, providing a cushion for debt service and dividends. The payout ratio of 275.8% is unsustainable in the long term, but the company has historically maintained dividends through cash flow and debt issuance.
FAQ
The key risks include: 1) Financial risk from high debt levels, with a negative debt-to-equity ratio of -21.1x and interest expenses of $717M, which could strain earnings if rates rise. 2) Competitive risk from biosimilars and GLP-1 drugs, which could erode market share. 3) Regulatory risk, as seen with the FDA rejection for TrenibotE, which could delay pipeline monetization. 4) Macro risk from drug tariffs and healthcare policy changes. The most severe risk is a major pipeline failure, which could lead to a 20% downside to the low target of $200.
The 12-month forecast is moderately bullish. The base case (50% probability) targets $250-$280, with the stock trading near the analyst average of $268.68. The bull case (30% probability) targets $280-$328, driven by pipeline successes and strong growth. The bear case (20% probability) targets $200-$220, due to potential setbacks. The most likely scenario is the base case, assuming steady growth and no major negative surprises. The key assumption is that Skyrizi and Rinvoq continue to offset Humira's decline and drive revenue growth of 10-12%.
ABBV is fairly valued to slightly undervalued. The forward PE of 15.4x is below the industry average of 18-20x, suggesting a discount. The trailing PE of 96.4x is misleading due to one-time charges, but the forward multiple is more indicative. Historically, the stock has traded at PE ratios ranging from 15x to 84x, and the current forward PE is near the lower end, implying reasonable valuation. The market is pricing in significant earnings growth, as evidenced by the wide gap between trailing and forward PE, but this is supported by the company's growth trajectory.
Yes, ABBV is a good buy for long-term investors. The stock offers a 7.1% upside to the average analyst target of $268.68, and its forward PE of 15.4x is below the sector average, indicating undervaluation. The main downside risk is a potential decline to the 52-week low of $189.79, which would represent a 24% loss. However, the strong growth from Skyrizi and Rinvoq and a robust pipeline make it a compelling risk/reward proposition. It is particularly suitable for income investors due to its 2.87% dividend yield and Dividend King status.
ABBV is more suitable for long-term investment due to its defensive characteristics (beta of 0.283) and dividend income. The stock has low volatility, making it less attractive for short-term trading. The earnings visibility is high, supported by a strong pipeline and stable revenue streams. A minimum holding period of 3-5 years is recommended to fully capture the growth from Skyrizi, Rinvoq, and pipeline drugs. Short-term investors may find limited upside, as the stock is near its 52-week high and could be subject to market volatility.